Principal Investigator, ISIS 696844-CS5. A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an antisense inhibitor of complement factor B, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration (AMD).

Project: Research

Project Details

StatusActive
Effective start/end date20/01/20 → …